Rajiv Shah, MD
Ophthalmology · Winston Salem, NCNPI 1396986329
Payments from drug & device makers
Across 797 payments — averaging $1592.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$302K
- Regeneron Healthcare Solutions, Inc.$253K
- Roche TCRC, Inc.$124K
- Gilead$110K
- AbbVie$101K
- Genentech, Inc.$99K
- plus $280K from 20 others
Across 1 payment — averaging $61.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$61
What the payments were for
- Consulting fees$84,9429%
- Speaking & faculty fees$716,36079%
- Travel & lodging$78,7189%
- Food & beverage$28,2353%
- Education$3780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 135 | $301,836 |
| Regeneron Healthcare Solutions, Inc. | 157 | $252,997 |
| Roche TCRC, Inc. | 22 | $123,903 |
| Gilead | 21 | $110,241 |
| AbbVie(2 entities) | 103 | $100,882 |
| Genentech, Inc. | 40 | $99,076 |
| Mallinckrodt Enterprises LLC | 32 | $77,985 |
| Amgen(2 entities) | 107 | $74,308 |
| Bausch & Lomb Americas Inc. | 44 | $28,062 |
| Bayer | 9 | $24,255 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 26 | $21,604 |
| Alimera Sciences, Inc. | 15 | $12,281 |
| Novartis | 15 | $9,793 |
| Genentech USA, Inc. | 13 | $6,703 |
| ANI Pharmaceuticals, Inc. | 6 | $6,623 |
| Eyepoint US, Inc. | 18 | $5,309 |
| Regeneron | 6 | $4,691 |
| F. Hoffmann-la Roche AG | 2 | $2,956 |
| Boehringer Ingelheim | 3 | $2,279 |
| Alcon | 9 | $1,829 |
| Dutch Ophthalmic, USA | 4 | $444 |
| Astellas Pharma US Inc | 3 | $379 |
| Apellis Pharmaceuticals, Inc. | 4 | $319 |
| Samsara Vision | 1 | $139 |
| Nova Eye, Inc. | 1 | $80 |
| Carl Zeiss Meditec USA, Inc. | 1 | $35 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,269,009 in reported general payments places this provider in the 95th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 595 | $4,268,450 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 86 | $2,244,165 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 47 | $1,184,395 |
| TepezzaTeprotumumab-Trbw | 16 | $894,340 |
| ActharCorticotropin | 16 | $712,544 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 40 | $667,808 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 22 | $341,322 |
| Humira(Cf) Pen Psor-Uv-Adol HsAdalimumab | 21 | $272,805 |
| Humira(Cf)Adalimumab | 29 | $202,586 |
| InflectraInfliximab-Dyyb | 13 | $130,555 |
| RemicadeInfliximab | 22 | $88,714 |
| Mycophenolate Mofetil | 593 | $82,010 |
| ActemraTocilizumab | 14 | $43,007 |
| LumiganBimatoprost | 86 | $42,874 |
| RhopressaNetarsudil Mesylate | 63 | $37,249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenTepezza | $74,308 | $894,34016 claims |
| Mallinckrodt Hospital Products Inc.Acthar | $301,836 | $712,54416 claims |
| AbbVieHumira(Cf), Lumigan, Restasis, Combigan | $100,882 | $279,512155 claims |
| Genentech, Inc.Actemra | $99,076 | $43,00714 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $21,604 | $37,481107 claims |
| NovartisIlevro | $9,793 | $11,47722 claims |
| AlconAzopt, Simbrinza | $1,829 | $10,83526 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 588 ophthalmology providers in North Carolina.
Other ophthalmology in Winston Salem
- Keith WalterWinston Salem$583K
- Craig GrevenWinston Salem$359K
- Vishak JohnWinston Salem$169K
- Jiaxi DingWinston Salem$43K
- Glenn JaffeDurham$38.5M
- Lejla VajzovicDurham$7.5M
- Andrew AntoszykCharlotte$4M
- Majda HadziahmetovicDurham$2.4M
- Preeya GuptaRaleigh$2M
- Thomas WilliamsHickory$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.